The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...

Dexcom has won FDA clearance of the Smart Basal, a CGM-integrated basal insulin dosing optimizer designed for adults with Type 2 diabetes on glargine U-100 long-acting insulin therapy. The clearance ...

What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many shareholders. This may have investors wondering how to approach the situation. Given ...

Dexcom recalled an Android app for its G6 continuous glucose monitor because of a problem with the app stopping unexpectedly. This story was originally published on MedTech Dive. To receive daily news ...

Earnings call Dexcom reported Q3 2025 revenue of $1.21B, up 22% YoY (20% organic), with EPS reaching a record $0.61. U.S. and international growth remained strong, especially in Type 2 diabetes ...

The U.S. Food and Drug Administration said on Tuesday that it will limit regulation of wearable devices and software designed to support healthy lifestyles, issuing new guidance to clarify its ...

Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as the continuous glucose monitoring (CGM) equipment maker managed to retain ...

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...

Learn effectively with tutorials and guides! Put your learnings into practice for optimal understanding and retention. King Charles III reveals major cancer update in rare message Trump's approval ...

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the start of 2026, succeeding Kevin Sayer, who will step down after a decade of ...